Enliven Therapeutics (ELVN) News Today $29.25 -0.30 (-1.02%) (As of 12:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy RecommendationOctober 31, 2024 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $178,500.00 in StockOctober 31, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 716 SharesOctober 23, 2024 | insidertrades.comAnish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 716 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00. Following the sale, the chief operating officer now owns 343,311 shares in the company, valued at approximately $10,299,330. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.October 22, 2024 | marketbeat.comWhy this largely unknown company is one analyst's top biotech pickOctober 19, 2024 | finance.yahoo.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year High - What's Next?Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High - Here's What HappenedOctober 18, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 SharesOctober 18, 2024 | insidertrades.comRichard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total value of $35,140.90. Following the completion of the transaction, the director now owns 124,490 shares of the company's stock, valued at approximately $3,444,638.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.October 17, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Up 10.3% in SeptemberEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,100,000 shares, an increase of 10.3% from the September 15th total of 5,530,000 shares. Approximately 21.1% of the company's shares are short sold. Based on an average trading volume of 241,600 shares, the days-to-cover ratio is currently 25.2 days.October 15, 2024 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of StockOctober 11, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 16,710 SharesOctober 11, 2024 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5.6% - Should You Sell?October 10, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,270 SharesOctober 9, 2024 | insidertrades.comRichard A. Heyman Sells 2,825 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 2,825 shares of the business's stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $27.51, for a total transaction of $77,715.75. Following the completion of the sale, the director now owns 125,760 shares in the company, valued at $3,459,657.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.October 8, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Still a Buy?October 7, 2024 | marketbeat.comOutperform Rating for Enliven Therapeutics’ ELVN-001 Based on Strong Efficacy and Safety Profile in CML TreatmentOctober 5, 2024 | markets.businessinsider.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 518 SharesOctober 4, 2024 | insidertrades.comRichard A. Heyman Sells 518 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 518 shares of the business's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,265.72. Following the completion of the transaction, the director now directly owns 128,585 shares of the company's stock, valued at $3,541,230.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.October 3, 2024 | marketbeat.comEnliven Therapeutics shares hold Buy rating on trial dataOctober 2, 2024 | uk.investing.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $50,660.00 in StockOctober 2, 2024 | insidertrades.comMarshall Wace LLP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Marshall Wace LLP bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 192,100 shares of the company's stock, valued at approximately $4,489,000. MarOctober 2, 2024 | marketbeat.comEnliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug CandidateOctober 2, 2024 | markets.businessinsider.comEnliven Therapeutics (NASDAQ:ELVN) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday.October 1, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Enliven Therapeutics (ELVN), Harmony Biosciences Holdings (HRMY)October 1, 2024 | markets.businessinsider.comNasdaq Celebrates 25 Years of MarketSite in Times SquareSeptember 30, 2024 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)September 30, 2024 | markets.businessinsider.comEnliven Therapeutics’ ELVN-001 shows promise in Phase I CML trialSeptember 30, 2024 | finance.yahoo.comEnliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia PatientsSeptember 29, 2024 | markets.businessinsider.comEnliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaSeptember 28, 2024 | globenewswire.comLogos Global Management LP Lowers Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Logos Global Management LP decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 62.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 595,000 shares of the company's stock after selling 979,220 shares duringSeptember 24, 2024 | marketbeat.comEnliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CMLSeptember 18, 2024 | globenewswire.comBank of New York Mellon Corp Acquires 37,632 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Bank of New York Mellon Corp boosted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 49.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 114,109 shares of the company's stock after purchasiSeptember 16, 2024 | marketbeat.comFirst Turn Management LLC Invests $9.66 Million in Enliven Therapeutics, Inc. (NASDAQ:ELVN)First Turn Management LLC bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 413,243 shares of the company's stock, valued at approximately $9,September 13, 2024 | marketbeat.comEnliven Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.46) Per Share, HC Wainwright Forecasts (NASDAQ:ELVN)Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright issued their Q3 2024 EPS estimates for Enliven Therapeutics in a research report issued to clients and investors on Monday, September 9th. HC Wainwright analyst R. Burns anticipates that the company will post earniSeptember 11, 2024 | marketbeat.comHC Wainwright Weighs in on Enliven Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ELVN)Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Enliven Therapeutics in a report released on Monday, September 9th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.52) per share fSeptember 10, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Quotes, Forecast and News SummarySeptember 9, 2024 | benzinga.comHC Wainwright & Co. Initiates Coverage of Enliven Therapeutics (ELVN) with Buy RecommendationSeptember 9, 2024 | msn.comEnliven Therapeutics (NASDAQ:ELVN) Trading Up 8.9%Enliven Therapeutics (NASDAQ:ELVN) Shares Up 8.9%September 9, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Now Covered by HC WainwrightHC Wainwright assumed coverage on Enliven Therapeutics in a research note on Monday. They issued a "buy" rating and a $37.00 price target on the stock.September 9, 2024 | marketbeat.comAnalysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Ascendis Pharma (ASND)September 9, 2024 | markets.businessinsider.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,000 Shares of StockSeptember 4, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $269,880.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,000 shares of the business's stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now owns 1,077,936 shares in the company, valued at $24,242,780.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.September 3, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading Up 4.8%Enliven Therapeutics (NASDAQ:ELVN) Shares Up 4.8%September 3, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $95,795.00 in StockSeptember 1, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 4,250 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 4,250 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.54, for a total value of $95,795.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.August 29, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 SharesAugust 29, 2024 | insidertrades.comSamuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $22.89, for a total value of $274,680.00. Following the completion of the sale, the chief executive officer now owns 1,049,255 shares in the company, valued at $24,017,446.95. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.August 28, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth PlansAugust 24, 2024 | finance.yahoo.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of StockAugust 20, 2024 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4%Enliven Therapeutics (NASDAQ:ELVN) Trading Down 4%August 19, 2024 | marketbeat.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future. To claim your copy, follow this link ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼-0.150.39▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼13▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avadel Pharmaceuticals News Today Intellia Therapeutics News Today Delcath Systems News Today Editas Medicine News Today Fulcrum Therapeutics News Today bluebird bio News Today CRISPR Therapeutics News Today Corcept Therapeutics News Today BridgeBio Pharma News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 11/7/2024 by MarketBeat.com Staff From Our Partners24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
